Granules India’s Net Profit For The First Quarter Of Financial Year 2020 Increases By 61%
Mumbai, 30th July 2019: Granules India Ltd., a growing pharmaceutical manufacturing company, announced today its result for its first quarter of the financial year 2020.
|CONSOLIDATED FINANCIALS||Q1FY’20||Q1FY’19||Growth (Y-o-Y)|
|Income from Operation||INR 595 Crs.||INR 453 Crs.||31%|
|Operating Profit||INR 119 Crs.||INR 73 Crs.||63%|
|Operating Profit Margin||19.9 %||16.0 %|
|Net Profit||INR 83 Crs.||INR 52 Crs.||61%|
|Net Profit Margin||13.9 %||11.1 %|
|STANDALONE FINANCIALS||Q1FY’20||Q1FY’19||Growth (Y-o-Y)|
|Income from Operation||INR 568 Crs.||INR 440 Crs.||29%|
|Operating Profit||INR 119 Crs.||INR 70 Crs.||70%|
|Operating Profit Margin||20.9 %||15.8 %|
|Net Profit||INR 60 Crs.||INR 40 Crs.||50%|
|Net Profit Margin||10.5 %||8.6 %|
The Company’s Board of Directors has approved the first interim dividend of 25 paise per share of the face value of Re. 1 each.
“We continue our growth momentum with the first quarter of FY20 showing encouraging results. Our total revenue from operations increased by 31% and net profit by 61% compared to the same period of the previous year. The sustained growth in our high volume based molecules business and our unwavering focus on the US market enabled us to achieve the growth. One of the key pillars of our business model has been driving operational efficiencies and along with it, a better product mix helped us improve the Operating and Net profit margins in this quarter. During the quarter we have filed 3 ANDAs and received approval for 2 ANDAs from US FDA filed earlier. In continuation to our commitment to improve the leverage position of the Company, this quarter has also witnessed improvement in our net debt position.” said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited.